Everolimus Versus Axitinib as Second‐line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy

[1]  E. Jonasch,et al.  Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review , 2016, Current medical research and opinion.

[2]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[3]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[4]  Billy Amzal,et al.  An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. , 2015, Clinical therapeutics.

[5]  T. Choueiri,et al.  Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. , 2015, European urology.

[6]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[7]  C. Kollmannsberger,et al.  Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies , 2014, PloS one.

[8]  T. Choueiri,et al.  A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma. , 2014, Clinical genitourinary cancer.

[9]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[10]  B. Escudier,et al.  Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients. , 2013, European journal of cancer.

[11]  Lauren McCann,et al.  A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.

[12]  J. Larkin,et al.  Current and future systemic treatments for renal cell carcinoma. , 2013, Seminars in cancer biology.

[13]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[14]  Xin Huang,et al.  Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[16]  Bohuslav Melichar,et al.  Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial , 2007, The Lancet.

[17]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.